Skip to main content

Table 6 Base case analysis: 1-year budget impact analysis of DEX, BORT and LEN/DEX

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Treatment regimen

Pharmaceutical costs

Non-pharmaceutical costs

Total costs

Percentage increase from SOC

DEX (SOC)

R 39 877

R 1 333 944

R 1 373 821

 

BORT

R 38 805 287

R 5 655 928

R 44 461 215

3136%

LEN/DEX

R 119 485 065

R 1 189 559

R 120 674 625

8684%